-
Mashup Score: 0
/PRNewswire/ — Optellum, the leader in AI-enabled lung cancer diagnosis, today announced it has entered a strategic agreement with Volpara Health, a Lunit…
Source: www.prnewswire.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Keragon, an AI-powered healthcare automation platform, secured a $7.5M seed round six months post-launch, bringing its total funding to $10.5M - 15 day(s) ago
/PRNewswire/ — Keragon, an AI-powered, HIPAA-compliant automation platform for healthcare, has raised $7.5 million in an oversubscribed seed funding round led…
Source: www.prnewswire.comCategories: General Medicine News, General HCPsTweet-
.@KeragonHQ an #AI-powered #healthcare #automation platform, secured a $7.5M seed round six months post-launch, bringing its total funding to $10.5M https://t.co/xVFz1Y4KeJ
-
-
Mashup Score: 0
/PRNewswire/ — Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe), the global home for digital…
Source: www.prnewswire.comCategories: General Medicine News, Future of MedicineTweet-
The Digital Medicine Society (DiMe) has released new resources to support the development of digital health technologies to predict and manage cancer immunotherapy side effects. #DigitalHealth #Oncology #Cancer https://t.co/W8q3czLj1k
-
-
Mashup Score: 1Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial - 26 day(s) ago
/PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug…
Source: www.prnewswire.comCategories: General Medicine News, Oncologists1Tweet-
🚨 News 🚨 The phase III MIRACLE trial (NCT06788756) of annamycin + cytarabine for patients with R/R AML receives first country approval in Europe to commence recruitment, following the successful phase IB/II MB-106 study. 👉 https://t.co/f0EdyD45yg #AMLsm #MedEd #MedNews #Leusm https://t.co/drICeWExC8
-
-
Mashup Score: 0
“Revolutionary portable device leverages advanced magnetic resonance technology to rapidly detect acute stroke biomarkers, enabling frontline care teams to…
Source: www.prnewswire.comCategories: General Medicine News, General HCPsTweet-
#Stroke Detection Innovator @Wellumio Enrolls First Patient in #Australia #ClinicalTrial for 'Axana' 0.1T portable magnetic resonance imaging device (Portable #MRI study) https://t.co/RhdU2A0Ft1
-
-
Mashup Score: 2Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis - 28 day(s) ago
/PRNewswire/ — KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the “NMPA”) of China has recently approved the…
Source: www.prnewswire.comCategories: General Medicine News, Allergy-ImmunologyTweet-
Keymed Biosciences Announces National Medical Products Administration Approval of #Stapokibart For the Treatment of Seasonal #Allergic #Rhinitis. https://t.co/FuYwSCPEMR https://t.co/tIVz4xbcxN
-
-
Mashup Score: 5Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis - 28 day(s) ago
/PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for…
Source: www.prnewswire.comCategories: General Medicine News, Allergy-ImmunologyTweet-
Nektar Therapeutics Receives #FDA Fast Track Designation for #Rezpegaldesleukin for the Treatment of Moderate-to-Severe #Atopic #Dermatitis. https://t.co/mfUFad9Wcv https://t.co/vNYgRX7i4v
-
-
Mashup Score: 0
/PRNewswire/ — Medsender, the AI-powered workflow automation platform for healthcare providers, is pleased to announce a recent $5 million Series A investment…
Source: www.prnewswire.comCategories: General Medicine News, General HCPsTweet-
.@MedsenderInc Series A Funding: leverages #AI to synchronize data from unstructured sources, automating admin workflows & patient comms; automates complex tasks like processing referrals, scheduling, and managing patient requests | #operationalefficiency https://t.co/6fA9acJiwv
-
-
Mashup Score: 24
/PRNewswire/ — Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the REZILIENT1 trial, a Phase 1/2…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet-
The Phase 2b REZILIENT1 study of zipalertinib (CLN-081/TAS6417) met its primary endpoint of response rate in patients with #EGFR exon 20 insertion mutation NSCLC. https://t.co/aFaQllG0x2
-
-
Mashup Score: 1IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Singapore Health Sciences Authority (HSA) - 1 month(s) ago
/PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of…
Source: www.prnewswire.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 Singapore @HSAsg accepts a New Drug Application for equecabtagene autoleucel, a BCMA-directed CAR T-cell therapy, for the treatment of R/R #MultipleMyeloma after ≥3 prior lines of therapy. Read more: https://t.co/UIxN7dn9VO #mmsm #myeloma #MedNews #MedEd https://t.co/YaK4JKKY8l
-
.@Optellum and @Volpara Announce Agreement for #LungCancer & #BreastCancer Care | #radiology #AI https://t.co/HWlMEdcyBx